Personalized Medicine through Genomic Analysis and Molecular Diagnostics
March 31, 2008, Boston, Massachusetts
Enter “CONNEXON” at checkout and receive 10% off registration.
Click here to register today.
Identification Of A Novel Neural Stem Cell Type
Researchers from the Sloan-Kettering Institute, led by Dr. Lorenz Studer, have discovered a novel type of neural stem cell, which has a broader differentiation potential than previously identified neural stem cells.
Stem Cells Modified to Home in Where They’re Needed
U.S. researchers have found a way to modify the surface of stem cells to direct them to where they’re needed, an advance that may prove useful in many areas of stem cell therapy.
Stem Cell Research Aims to Tackle Parkinson’s Disease
Scientists in Sweden are developing new ways to grow brain cells in the laboratory that could one day be used to treat patients with Parkinson’s disease.
Study Gives Insight Into Hair Growth
Researchers at USC have identified a new mechanism that controls the activation of stem cells during hair regeneration.
Researchers Create New Rat Heart in Lab
The researchers removed all the cells from a dead rat heart, leaving the valves and outer structure as scaffolding for new heart cells injected from newborn rats. Within two weeks, the new cells formed a new beating heart that conducted electrical impulses and pumped a small amount of blood.
Gene Therapy Technique: Water Droplets Produced By Electrospray Render Cells Permeable To External DNA
Japanese researchers have now developed a method which could represent a true alternative to conventional processes. The cells are “bombarded” with water droplets produced and accelerated by electrospray.
Pigs Raise Hopes for Blindness Cure
Pioneering transplants to restore the sight of people affected by the leading cause of blindness in the Western world could start in three years, after successful human cell implants in pigs.
Aastrom Announces First Patient Treatment With Autologous Stem Cell Therapy for Heart Failure
Aastrom Biosciences, Inc. has announced that the first patient has been treated with the Company’s autologous stem cell therapy for dilated cardiomyopathy.
StemCells, Inc. Provides Batten’s Clinical Trial Update
StemCells, Inc. has provided an update on the Company’s Phase I clinical trial of its proprietary HuCNS-SC(R) product candidate.
Gene Therapy Implants for Tendons
Freeze-dried implants loaded with gene therapy solution are being developed which may help repair injured and difficult-to-treat tendons.
Gene Therapy Cancers Prompt Design of Safer Virus
The announcement last month that a fifth child who received gene therapy for an immune system disease has developed leukemia was the latest blow to the field of gene therapy. But there’s new hope: The U.K. team running the trial reports this week that a safer formulation of the treatment can cure the disease in mice and should also work in people.
Nucleonics Initiates Hepatitis B Clinical Trial with Expressed Interfering RNA Therapeutic
Nucleonics, Inc. has announced that the company has begun treating patients in a Phase 1 human safety study of its experimental treatment for chronic Hepatitis B virus infection, NUC B1000.
Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase III Wrinkle and Phase II Full Face Studies
Isolagen(TM), Inc. has announced that injections have been completed in the pivotal Phase III multi-center, double-blind, randomized, placebo-controlled clinical trials evaluating the Isolagen Therapy(TM) for the treatment of nasolabial folds, or wrinkles (Studies IT-A-005 and IT-A-006).
Interim Analysis Supports Continuation of Cell Genesys’ VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
Cell Genesys, Inc. has announced that the Independent Data Monitoring Committee for VITAL-1, the first of two ongoing Phase 3 clinical trials of GVAX immunotherapy for prostate cancer, has completed a pre-planned interim analysis and has recommended that the study continue.
ABSTRACTS, REVIEWS AND SPECIAL REPORTS
Human Embryonic Stem Cell-derived Cardiomyocytes Survive and Mature in the Mouse Heart and Transiently Improve Function After Myocardial Infarction
Researchers show the results of the first long-term (12 weeks) analysis of the fate of HESC-derived cardiomyocytes transplanted intramyocardially into healthy, immunocompromised (NOD-SCID) mice and in NOD-SCID mice that had undergone myocardial infarction.
Development of a Clinical Model for Ex Vivo Expansion of Multiple Populations of Effector Cells for Adoptive Cellular Therapy
The goal of these experiments was to develop a good manufacturing practice (GMP) method for expanding clinical-grade activated effector cells that mediate tumor cell killing through various mechanisms that could be infused into patients following high-dose chemotherapy and autologous stem cell transplant.
Cell Therapy Business Development Leader
Portland, OR (Invitrogen)
Irvine, CA (Global Biopharmaceutical Company)
Biomedical Equipment Technician
Los Angeles, CA (Cedars-Sinai Medical Center)
Singapore (Singapore Cord Blood Bank)